Fochon Pharmaceuticals Ltd.

Main study objectives: To evaluate the effects of itraconazole capsules and rifampicin capsules on the main pharmacokinetic parameters of succinate succinate succinate succinate capsules in healthy Chinese subjects; Secondary study objectives: 1) To evaluate the effects of itraconazole capsules and rifampicin capsules on other pharmacokinetic parameters of succinate succinate succinate capsules in healthy Chinese subjects; 2) To evaluate the safety of single-dose oral administration of succinate succinate succinate capsules and combined administration with itraconazole capsules and rifampicin capsules in healthy Chinese subjects; Exploratory objectives: To qualitatively analyze the metabolites in feces of healthy Chinese subjects after single-dose oral administration of succinate succinate succinate capsules and combined administration with itraconazole capsules and rifampicin capsules.

Primary study objective: To evaluate and compare the pharmacokinetic characteristics of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects, and to provide a basis for clinical medication in patients with liver impairment Secondary study objective: To evaluate the safety of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects

Primary objectives: To evaluate the safety and tolerability of FCN-338 combined with AZA or chemotherapy (cytarabine, daunorubicin) in patients with myeloid neoplasms. To explore the efficacy of FCN-338 combination therapy in patients with myeloid neoplasms. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of FCN-338 combination therapy in patients with myeloid neoplasms. 2) To evaluate the transfusion independence rate of FCN-338 combination therapy in patients with myeloid neoplasms. 3) To evaluate the hematological improvement (HI) of FCN-338 combination therapy in patients with MDS/CMML.